cyrilzakka/clinical-trials huggingface dataset:
Establishing the Chaplain Role in a Primary Care Clinic Setting

In 2019, a full-time chaplain was placed in the Golden Cross Academic Clinic (GCAC), with the chaplain's focus being in the primary care internal medicine department. While research exists regarding chaplains in the inpatient setting, research regarding the presence of a full-time chaplain in a primary care setting as well as the topics patients discuss with that chaplain are limited.

A few studies conducted in the hospital setting have shown what topics patients typically discuss with a chaplain. In the article, "Patients and Loved Ones' Expectations of Chaplain Services. Munchausen and colleagues present that the two highest-rated services performed by chaplains were spiritual and emotional support. This study also found that patients wanted to see a chaplain for the following reasons: to be listened to, to be with in times of anxiety, to offer support to loves ones, to remind of God's care and presence, to pray, for religious rituals, to assist with the understanding of advance care planning documents, and to counsel regarding moral or ethical decisions.

Eligibility Criteria:
Inclusion Criteria:

* • Patient at the GCAC who are \> 18 years old

  * Met with a member of the on-staff chaplaincy during a visit to GCAC

Exclusion Criteria:

* • Patient did not meet with a member of the on-staff chaplaincy during a visit to GCAC
Pharmacokinetics of Levofloxacin in Intensive Care Unit

The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients suffering from pneumonia with taking into account physio-pathological parameters. 2. to verify clinical and bacteriological efficiency and to know if the peak/Minimum Inhibitory Concentration (MIC) ratio \> 5 and Area Under Curve (AUC) /Minimum Inhibitory Concentration(MIC) ratio \> 125. No therapeutic drug monitoring will be performed in this study.


Eligibility Criteria:
Inclusion Criteria:

* severe community-acquired pneumonia due to a strain sensible to levofloxacin
* Age \> 18 years
* Informed consent
* SAPS II (simplified acute physiological score) \> 20 Awaited duration of survival higher than 7 days

Exclusion Criteria:

* Historic of allergy to levofloxacin
* Resistant strain to levofloxacin
* Pregnancy
* Contra-indications of levofloxacin use, renal failure
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.


Eligibility Criteria:
Inclusion Criteria:

All patients had histologically or cytologically confirmed locally advanced NSCLC. All patients must not have undergone any previous therapy for NSCLC. Patients had to have measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and to be less than 75 years old. Adequate organ (bone marrow, renal, liver, heart, and lung) function was required. All patients gave written informed consent.

Exclusion Criteria:

The exclusion criteria consisted of pulmonary fibrosis, pleural effusion, pregnancy, lactation, active concurrent malignancies, severe drug allergies, myocardial infarction, severe heart disease, uncontrollable diabetes mellitus, and infection. -
Clinical Characteristics of Severe Childhood Asthma

Asthma remains a serious health problem with increasing prevalence and incidence. There is limited information about severe asthma among Chinese pediatric patients. In this context, we decided to explore the clinical characteristics and risk factors of severe asthma in children. This is a descriptive, observational, retrospective cohort study in children with asthma.

The purpose of this retrospective study is: to determine the clinical characteristics of severe asthma of children; to identify the factors associated with severe childhood asthma.

Asthma remains a serious health problem with increasing prevalence and incidence. There is limited information about severe asthma among Chinese pediatric patients. In this context, we decided to explore the clinical characteristics and risk factors of severe asthma in children. This is a descriptive, observational, retrospective cohort study in children with asthma.

The purpose of this retrospective study is: to determine the clinical characteristics of severe asthma of children; to identify the factors associated with severe childhood asthma.

Participants were consecutively recruited from asthma clinics between January 2021 and December 2021 at Children's Hospital of Fudan University. Patients fulfilling the following criteria were eligible for inclusion: (1) aged 6-17 years old; (2) diagnosed with asthma according to the Global Initiative for Asthma (GINA) 2020 guideline; (3) children and their caregivers are informed and voluntarily join the database and had follow up for at least 1 year. Patients who had cystic fibrosis, mechanical airway obstruction, or any other pulmonary disease or whose parents or legal guardians were not able to fill in the questionnaires were not enrolled.

At baseline, the asthma specialist questioned each of the patient in the presence of their caregivers to ensure that they supplied accurate disease information and were included according to the criteria. The patients and their caregivers are asked to complete the online questionnaires including the demographic; baseline asthma control, triggers, exacerbation, medication and adherence; environmental exposure, and diagnosis and control of comorbidities, etc. If a patient had poorly controlled comorbidities, multidisciplinary consultation would be recommended. Clinical assessments were arranged at baseline, 3, 6, 9, and 12 months.

Eligibility Criteria:
Inclusion Criteria:

* (1) aged 6-17 years old;
* (2) diagnosed with asthma according to the Global Initiative for Asthma (GINA) 2020 guideline;
* (3) children and their caregivers are informed and voluntarily join the database and had follow up for at least 1 year.

Exclusion Criteria:

* (1) Patients with cystic fibrosis;
* (2) had mechanical airway obstruction, or any other pulmonary disease;
* (3) whose parents or legal guardians were not able to fill in the questionnaires.
A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

Venous leg ulcers are lower extremity ulcers that develop due to sustained venous hypertension resulting from chronic venous insufficiency. Varicose veins, deep vein thrombosis, poor calf muscle function, arterio-venous fistulae, obesity and history of leg fracture are some of the risk factors for venous ulceration. Numerous dressing types exist to treat these ulcers. This study will compare a marine polysaccharide (MPS) dressing to a carboxymethylcellulose dressing to determine which dressing better manages these wounds with regard to wound size and periwound skin condition. Subjects will be randomized to receive either MPS-Ag dressing or CMC-Ag dressing.


Eligibility Criteria:
Inclusion Criteria:

* Subject is able and willing to comply with requirements of this trial protocol
* Voluntarily signed informed consent before any trial related procedures are performed
* Subjects must be able to communicate effectively with study personnel
* Subject has lower extremity venous ulcer wound, as determined by site PI.
* Subject has adequate circulation as determined by biphasic or triphasic Doppler waveform, consistent with adequate blood flow, within three months prior to study enrollment. If monophasic on exam, then non-invasive tests must display Ankle Brachial Index over 0.8 and no worse than mild disease on segmental pressures.
* Subjects should not be allergic to silver (Ag).
* Size of subject's wound is between 1 squared centimeter and 100 squared centimeters.
* Duration of subject's wound is less than 52 weeks.

Exclusion Criteria:

* Subjects who are pregnant, nursing, or planning to become pregnant during the course of the study.
* Subjects who have known allergies to any ingredient(s) in the clinical products used in this study.
* Subjects who do not wish to use products derived from shellfish.
* Subjects with substance use disorder.
* Subjects with active infection or currently receiving antibiotic treatment.
* Subjects who are currently enrolled in another research study which includes investigational treatment and/or medication.
* Subjects judged by the investigator or sub-investigator to be inappropriate as a subject of this study.
* Subject has previous or current systemic disease(s) which, in the judgement of the site PI, is likely to interfere with the study. However, subjects with well-controlled diabetes mellitus (HbA1C \< 8.5) shall be permitted.
Provider-Patient Communication Coaching

To examine the effect of a coaching intervention on provider burnout and communication

The investigator will recruit providers at Duke University and randomly assign them to receive (1) a communication coaching intervention or (2) a waitlist intervention. The investigator will survey all providers at Baseline and Follow Up. Providers randomized to the intervention arm will attend face-to-face meetings with study coaches, and have some of their encounters with patients shadowed by a coach or audio recorded. Providers will obtain verbal consent from patients to participate in the study (i.e. have their encounter shadowed or audio recorded). Providers will then be provided feedback by coaches on their communication during these encounters. Providers randomized to the waitlist intervention arm will be offered the option of receiving this intervention after they complete the follow up survey.

Eligibility Criteria:
Inclusion Criteria:

* Providers and patients at Duke University Medical Center

Exclusion Criteria:

* Younger than 18
* non-English speaking
A Lifecourse Map of Diseases in China

The purpose of this study is to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group.

Studying the distribution of various diseases in specific populations can help explore the causes of diseases, elucidate the distribution patterns, and develop preventive and control measures. Based on an overall assessment of prevalence, the combination of relevant results with age at diagnosis for multiple diseases is important for further understanding of the distribution of diseases at the population level. Therefore, this study aims to form a chronological map of common diseases and rare diseases in Chinese population by determining the prevalence of different diseases in each age group, thus providing a reference for more effective prevention, diagnosis and treatment of diseases.

Eligibility Criteria:
Inclusion Criteria:

1. All inpatients within the period of January 1, 2017 to December 31, 2021.
2. Patients with discharge diagnosis.
3. Patients with accurate gender and age records.

Exclusion Criteria:

1. Morbidity and mortality due to external causes, i.e. injuries, poisonings and other adverse events due to external environment and accidents.
2. Pregnancy-related conditions.
3. Symptoms, signs, abnormal clinical and laboratory findings.
4. Traditional Chinese Medicine diagnosis records.
5. Patients with incorrect or missing disease codes.
Safety and Efficacy Study of the NeuGuide Device

This study aims to investigate the safety, efficacy, peri and postoperative complications, and patient satisfaction of sacro-spinous ligament fixation (SSLF) for the management of pelvic organ prolapse (POP).

Prolapse staging for all subjects in this study will be performed according to the POP-Q staging system.

Ultrasound examinations for all subjects in this study are subjected to the surgeon need and will be performed if required by qualified personnel


Eligibility Criteria:
Inclusion Criteria:

* Women ages 18-80 years old
* POP-Q stage III prolapse or higher
* Scheduled to undergo a POP Surgery and has agreed to undergo it using the NeuGuideTM device
* Patient is willing to return for follow-up evaluation and fill questionnaires as indicated on study protocol
* No exclusion criteria fulfilled

Exclusion Criteria:

* Diagnosis of reproductive tract anomalies
* Prior pelvic radiation therapy or any malignancy
* Inability to complete written questionnaires.
* Women with significant Pelvic Inflammatory Disease (PID) history
* Women with known allergy to Nickel or Nitinol
Respiratory Muscle Performance and Functional Capacity in Primary Stage IIIb and IV Lung Cancer

The purpose of our study is to investigate the association between respiratory muscle performance, functional capacity, dyspnea, anxiety/depression symptom, 1-year respiratory morbidity rate, and 1-year mortality in patients with primary stage IIIb and IV lung cancer.

Background and Purpose: Respiratory muscle function is important in sustaining the levels of physical activity required for daily life. The purpose of our study is to investigate the association between respiratory muscle performance, functional capacity, dyspnea, anxiety/depression symptom, 1-year respiratory morbidity rate, and 1-year mortality in patients with primary stage IIIb and IV lung cancer.

Methods: A total of 120 patients with newly diagnosed primary stage IIIb and IV lung cancer will be recruited from the National Taiwan University Hospital. Demographic and clinical signs/syndromes will be obtained from the chart. Pain and dyspnea will be measured using visual analog scale. Respiratory muscle strength will be tested by measuring maximal inspiratory and expiratory pressure (PImax and PEmax, respectively). Spirometric variables, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be measured. Functional capacity will be measured using Karnofsky performance status and Simmonds functional assessment. Anxiety/depression symptom will be measured using Hospital Anxiety and Depression Scale. One year respiratory complication morbidity and 1-year mortality will be recorded in prospective nature. Spearman's and Pearson correlation coefficient will be used to test the relationship between respiratory muscle performance and multiple variables. Univariate and stepwise multiple regression analyses will be used to identify factors associated with respiratory muscle performance, functional capacity, one-year respiratory morbidity and one-year mortality rate in patients with primary stage IIIb and IV lung cancer.

Clinical relevance: The prevalence of lung cancer is increasing in the recent years. The attempt to understand the relations between respiratory muscle performance, functional capacity and associated clinical courses will shed light on whether chest physical therapy intervention will be beneficial for patients with primary IIIb and IV lung cancer.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of stage IIIb/V lung cancer
* Normal cognition (a Mini Mental State Examination score of more than/equal to 24 points)
* Able to finish all tests

Exclusion Criteria:

* A clinical diagnosis affecting respiratory muscle function and functional activity performance (e.g. acute pneumonia)
Comparison of Intr-operative Neuromonitoring Technique in Trans-oral Endoscopic Thyroidectomy Vestibular Approach

Transoral endoscopic thyroidectomy vestibular approach (TOETVA) has the advantage of scarless cosmesis but has limitations of recurrent laryngeal nerve (RLN) palsy. Intermittent intraoperative neuromonitoring (I-IONM) techniques have been utilized during TOETVA to identify and map RLN to prevent RLN injury. However, the insult may still occur between two neural stimulations. Continuous intraoperative neuromonitoring (C-IONM) has been used in TOETVA to persistent stimulation of RLN. but only in our hospital. This rare use may be related to technical challenges. Recently, we successfully developed a novel technique of percutaneous C-IONM using an external fixator to secure the stimulation probe to steadily monitor the real-time functional status of RLN during the TOETVA. In this retrospective study, 304 patients undergone TOETVA were enrolled and divided according to the usage of IONM techniques into percutaneous or peroral intermittent and continuous groups. Patient's age, sex, BMI, thyroid disease, operation time, EMG signal and RLN palsy rate were compared to verified the feasibility, safety, and effectiveness of different IONM techniques. We hypothesized percutaneous C-IONM has the superiority in early detection of RLN injury and reducing of RLN palsy in TOETVA.


Eligibility Criteria:
Inclusion Criteria: Benign solitary or multiple thyroid nodules, follicular lesions (the largest diameter \<6.0 cm), and early papillary thyroid carcinoma (\<1 cm in diameter, without cervical lymphadenopathy)

Exclusion Criteria: History of thyroid surgery, neck radiotherapy, and recurrent laryngeal nerve paralysis; intraoperative conversion to conventional thyroidectomy.
Impact of tDCS on Cannabis Craving in Schizophrenia

This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.

The authors set up this randomized, double-blind multicenter study. 7 centers are participating in this research. After randomisation, the patient will have either the placebo or stimulation sessions, by tDCS, 5 session per day, for 5 days. The authors use the Marijuana Craving Questionnaire (MCQ) scale to determine the variation in cannabis craving and measure the impact of treatment on craving, as primary outcome.

secondary objectives include assessing the effect of tDCS on the general psychopathology of schizophrenia, cannabis and tobacco addiction, and on cognitive tests assessing attention and risk taking This study will be the first known multicenter study assessing tDCS impact on cannabis craving in schizophrenia.

Eligibility Criteria:
Inclusion Criteria:

1. Patients (male or female) aged 18-65
2. Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of "cannabis use disorder"
3. Stabilized patients: total score = 80 at initial PANSS score and = 3 at the following PANSS points:

   * conceptual disorganization
   * distrust
   * hallucinatory behaviour
   * Unusual content of thought
4. Patients without any other drug or psychotherapeutic treatment for cannabis dependence ("naive" patients)
5. Reported cannabis use greater than three times per week in the past three years
6. Signed consent to participate in research
7. Affiliation to a French social security scheme
8. Patient fluent in the French language

Exclusion Criteria:

1. Presence of any other psychiatric disorder, as per DSM-5 criteria.
2. Pregnancy, possible pregnancy due to lack of contraception, breastfeeding.
3. Currently active suicidal or self-injurious ideation (suicidal or not)
4. Patients with Serious medical codition
5. Other "moderate" to "severe" addictions, according to DSM 5 criteria (excluding tobacco and coffee).
6. Contraindications to tDCS (presence of intracranial metal material, intracranial hypertension, etc.).
7. Subjects already treated by tDCS
8. Patients under legal guardianship (except under curatorship)
9. Patients under safeguard of justice
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma( NPC ) patients.

Patients presented with non-keratinizing NPC and stage T1-4N2-3/T4N0-1M0 are randomly assigned to receive GP (gemcitabine and cisplatin) or PF (cisplatin and fluorouracil) induction chemotherapy combined with concurrent chemoradiotherapy. Patients in both arms receive radical radiotherapy, and cisplatin (100mg/m²) every three weeks for two cycles during radiotherapy. Patients in the investigational arm receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for three cycles. Patients in the control arm receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for three cycles. Our primary endpoint is progress-free survival (PFS). Secondary end points include distant metastasis-free survival (DMFS), overall survival (OS), locoregional relapse-free survival (LRRFS), initial response rates after treatments, toxic effects and quality of life (QoL).

Eligibility Criteria:
Inclusion Criteria:

* Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III
* Tumor staged as T1-4N2-3/T4N0-1M0（according to the 8th AJCC edition）
* Male and no pregnant female
* Age between 18-65
* Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL
* Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \<2.0×upper limit of normal (ULN)
* Adequate renal function: creatinine clearance ≥60 ml/min
* Satisfactory performance status: Karnofsky scale (KPS) ≥ 70
* Without radiotherapy or chemotherapy
* Patients must give signed informed consent

Exclusion Criteria:

* Evidence of relapse or distant metastasis
* History of prior malignancy or previous treatment for NPC
* Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), and emotional disturbance.
* Pregnancy or lactation